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Candidate-gene association studies in rheumatoid arthritis (RA) have lead to encouraging yet apparently inconsistent
results. One explanation for the inconsistency is insufﬁcient power to detect modest effects in the context of a low
prior probability of a true effect. To overcome this limitation, we selected alleles with an increased probability of
a disease association, on the basis of a review of the literature on RA and other autoimmune diseases, and tested
them for association with RA susceptibility in a sample collection powered to detect modest genetic effects. We
tested 17 alleles from 14 genes in 2,370 RA cases and 1,757 controls from the North American Rheumatoid
Arthritis Consortium (NARAC) and the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA)
collections. We found strong evidence of an association of PTPN22 with the development of anti-citrulline antibody–
positive RA (odds ratio [OR] 1.49; ), using previously untested EIRA samples. We provide support forPp .00002
an association of CTLA4 (CT60 allele, OR 1.23; ) and PADI4 (PADI4_94, OR 1.24; ) with thePp .001 Pp .001
development of RA, but only in the NARAC cohort. The CTLA4 association is stronger in patients with RA from
both cohorts who are seropositive for anti-citrulline antibodies ( ). Exploration of our data set withPp .0006
clinically relevant subsets of RA reveals that PTPN22 is associated with an earlier age at disease onset (Pp
) and that PTPN22 has a stronger effect in males than in females ( ). Ameta-analysis failed to demonstrate.004 Pp .03
an association of the remaining alleles with RA susceptibility, suggesting that the previously published associations
may represent false-positive results. Given the strong statistical power to replicate a true-positive association in this
study, our results provide support for PTPN22, CTLA4, and PADI4 as RA susceptibility genes and demonstrate
novel associations with clinically relevant subsets of RA.
Introduction
Rheumatoid arthritis (RA [MIM 180300]) is a common
autoimmune disease characterized by chronic, destruc-
tive, and debilitating arthritis (Gabriel et al. 1999). The
etiology of RA is unknown, but it is thought to have
both a genetic and an environmental basis (Firestein
2003). Autoantibodies are detected in ∼2/3 of patients
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with RA and predict more-severe disease (van Zeben et
al. 1992; van Jaarsveld et al. 1999; Kroot et al. 2000).
The two major types of autoantibodies used clinically
to create RA subsets are rheumatoid factor (RF), which
is an immunoglobulin speciﬁc to the Fc region of IgG,
and anti–cyclic citrullinated peptide (CCP) antibodies,
which are antibodies directed against peptides in which
arginine has been posttranslationally modiﬁed to be-
come citrulline (Schellekens et al. 2000). These auto-
antibodies are strongly correlated but may represent dis-
tinct clinical subsets of RA. For decades, it has been
known that HLA-DR alleles within the major histo-
compatibility complex (MHC) are associated with RA
(Stastny and Fink 1977) and are likely to contribute
∼1/3 of the genetic risk in RA (Deighton et al. 1989;
Rigby et al. 1991). Although theMHC associationswith
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RA are complex (Jawaheer et al. 2002; Newton et al.
2004), the majority of the genetic signal from the MHC
is explained by multiple alleles at the HLA-DRB1 locus
(MIM 142857) (Hall et al. 1996; Jawaheer et al. 2002).
These alleles are known collectively as “shared epitope”
(SE) alleles because of their sequence similarity within
the third hypervariable region (amino acids 70–74: Leu-
x-x-Glu-Arg/Lys [Gregersen et al. 1987]). Non-MHC
genes are likely to contribute to RA pathogenesis and
disease heterogeneity but have been much more difﬁcult
to identify.
Genetic association studies of RA applied to non-
MHC candidate genes have led to encouraging yet ap-
parently inconsistent results (see Genetic Association
Database Web site). One explanation for the inconsis-
tency is insufﬁcient power to detect modest effects in
the context of a low prior probability of a true effect
and the failure to assign a stringent P value to interpret
signiﬁcance (Hirschhorn and Daly 2005; Wang et al.
2005). Thousands of patients are required to detect an
allele with an odds ratio (OR) less than that observed
for HLA-DRB1, and the vast majority of association
studies of RA have been performedwith !1,000 samples
(notable exceptions include studies by Barton et al.
[2004b], Begovich et al. [2004], Prokunina et al. [2004],
Kochi et al. [2005], and Swanberg et al. [2005]). The
inconsistent results and lack of replication make inter-
preting the signiﬁcance of these association studies a
challenge, and it is difﬁcult to determine which results
are true positives and which are false positives.
In the current study, we sought to test alleles with a
prior putative association with RA or other autoim-
mune disorders in a collection of 4,127 samples (2,370
RA cases and 1,757 controls) powered to detect modest
genetic effects (Hirschhorn et al. 2002; Lohmueller et
al. 2003). Our goal was to determine which alleles rep-
licate in our collection from Sweden and North Amer-
ica, thus providing evidence of a true-positive associ-
ation. We ﬁrst performed a thorough review of the
literature on RA candidate-gene association studies, to
identify alleles with suggestive (but not deﬁnitive) evi-
dence of association with the development of RA. We
also reviewed the literature to identify alleles with con-
vincing evidence of association with autoimmune dis-
eases other than RA, since we hypothesized that com-
mon pathogenic mechanisms may be shared among RA
and other autoimmune diseases (Yamada and Ymamoto
2005). Here, we describe our results of testing 17 alleles
in 14 genes for association with RA susceptibility in
two independent clinical collections consisting of Swed-
ish or North American individuals of European descent.
Our results validate the hypothesis that the R620W
variant of PTPN22 (MIM 600716) is associated with
the development of RF-positive (RF) and anti-CCP–
positive (CCP) RA and provide support for an asso-
ciation of RA with variants in PADI4 (MIM 605347)
and CTLA4 (MIM 123890).
Material and Methods
Clinical Samples
Two case-control clinical collections were used to test
all 17 alleles for association between genetic variation
and the development of RA. Clinical characteristics for
both collections are provided in table 1. All individuals
are of European descent. In total, 4,127 samples (2,370
RA cases and 1,757 controls) were available for analysis.
This study was approved by the MIT Broad Institute
Institutional Review Board.
The ﬁrst cohort, the Epidemiological Investigation of
Rheumatoid Arthritis (EIRA), is an inception cohort col-
lected in Sweden betweenMay 1996 and February 2001.
This cohort has been described in more detail elsewhere
(Stolt et al. 2003; Padyukov et al. 2004). Brieﬂy, a case
is deﬁned as an individual who fulﬁlls the American
College of Rheumatology (ACR) 1987 criteria for the
classiﬁcation of RA (Arnett et al. 1988) and who has
never before been diagnosed with RA. For each potential
case, a control subject was randomly selected from the
study base, with the subject’s age, sex, and residential
area taken into consideration. In total, 1,530 conﬁrmed
RA cases and 881 controls were available for analysis.
Low-resolution HLA typing was performed on ∼94%
of the samples by use of the sequence-speciﬁc primer-
PCR method (HLA-DR low-resolution kit) as described
elsewhere (Olerup and Zetterquist 1992).
The second collection is the North American Rheu-
matoid Arthritis Consortium (NARAC). This collection
of affected sibling pairs has been described inmore detail
elsewhere (Jawaheer et al. 2001, 2004; North American
Rheumatoid Arthritis Consortium Web site). Brieﬂy, a
case is deﬁned as an individual who fulﬁlls the ACR
1987 criteria for RA and who has at least one sibling
with RA. At least one sibling must have documented
erosions on hand radiographs, and at least one sibling
must have disease onset between the ages of 18 and 60
years. In total, 840 affected cases from 463 families were
used in our analysis. Unrelated matched controls (np
) were selected from 20,000 healthy individuals who867
were enrolled in the New York Cancer Project (NYCP)
(see New York Cancer Project Web site). Two controls
were matched to a single randomly chosen affected sib-
ling on the basis of sex, age (birth decade), and ethnicity
(grandparental country/region of origin). Complete data
for PTPN22 (Begovich et al. 2004; Lee et al. 2005) and
partial data for CARD15 (Addo et al. 2005) have been
published elsewhere for this cohort. PADI4 genotype
data were generated at the National Institute of Arthritis
and Musculoskeletal and Skin Diseases (NIAMS) by use
of an overlapping set of NARAC and NYCP samples:
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Table 1
Clinical Characteristics of EIRA and NARAC Cohorts
Characteristic EIRA NARAC
No. of cases 1,530 840
No. of controls 881 876
Study design Unrelated cases with matched
unrelated controls
Affected sib cases with matched
unrelated controls
Ascertainment Incident cases (May 1996–
February 2001)
Radiographic erosions and 1
sibling aged 18–60 years
Geographic ancestry European European
Country of origin Sweden United States
Female sex (%) 70.6 77.4
Age at onset (mean  SD years) 51.7  12.8 39.4  13.1
Disease duration (mean  SD years) !3 16.2  11.8
Autoantibody positivity (%):
RF 66.2 78.2
CCP 60.9 77.8
RF or CCP 72.5 84.7
HLA SE status (allele frequency):
Any .49 .62
SE subtype:
HLA-DRB1*04 .34 .48
HLA-DRB1*01 .13 .14
HLA-DRB1*10 .01 .03
Clinical features (%):
Radiographic erosions Unknown 95.3
Thyroiditis (self-reported) Unknown 19
NOTE.—Details on the EIRA cohort (Stolt et al. 2003; Padyukov et al. 2004) and NARAC cohort
(Jawaheer et al. 2001, 2004) have been published elsewhere.
601 NARAC cases and NYCP controls were common
to the current data set, and 1,115 individuals were
unique.
In addition to these two cohorts, an additional col-
lection (“arthritis cohort 3”) of 1,417 patients with RA
(with no matched controls) was used to investigate the
inﬂuence of PTPN22 alleles on RA phenotype in males
and females and to study age-at-onset effects. These
samples were used in a case-only analysis comparing
allele frequencies in autoantibody-positive (RF and/or
CCP) disease with those in autoantibody-negative
(RF and/or CCP) disease. Consequently, no matched
controls were necessary. Patient samples were obtained
from the Wichita Rheumatic Disease Data Bank (Wolfe
et al. 2003); The Arthritis, Rheumatism and AgingMed-
ical Information System; the National Inception Cohort
of Rheumatoid Arthritis Patients (Fries et al. 2002) (130
RF male cases, 401 RF female cases, 42 RF male
cases, and 139 RF female cases); and the Study Of
New Onset Rheumatoid Arthritis (SONORA) (Bom-
bardier et al. 2002; S.O.N.O.R.A. Web site) (128 RF
male cases, 313 RF female cases, 70 RF male cases,
and 194 RF female cases). These RA sample sets were
combined, and, for comparison with the EIRA and
NARAC collections, only patients of European descent
were analyzed ( total RA cases).np 1,417
Literature Review
We reviewed the literature published in English before
December 31, 2004, to identify non-MHC alleles that
had results suggesting a putative association with RA.
Inclusion criteria for a putative susceptibility allele were
(a) location within a non-MHC gene; (b) association
with RA susceptibility—that is, the presence or absence
of RA (we did not include an allele when the reported
association was limited to a secondary phenotype, such
as disease severity, because our primary purpose was to
replicate previous associations with RA susceptibility);
(c) a SNP or insertion-deletion (indel) polymorphism
(i.e., no microsatellite markers); (d) genotyping in at least
200 patients with RA, with samples other than EIRA or
NARAC; and (e) signiﬁcance at a level !.001 in one
study or !.05 in two or more studies (nominal P values
based on allele frequencies in cases vs. controls). We
identiﬁed 1200 published association studies of RA.
From these studies, we identiﬁed 10 alleles within nine
genes that met our inclusion criteria for testing in our
combined RA sample collection (table 2). Speciﬁc alleles
at PADI4 (Suzuki et al. 2003), CTLA4 (Rodriguez et al.
2002; Vaidya et al. 2002), IL4 (Cantagrel et al. 1999;
Maksymowych et al. 2002), SLC22A4 (Tokuhiro et al.
2003), MIF (Barton et al. 2003), and TNFRSF1B (Bar-
ton et al. 2001; Dieude et al. 2002; Kyogoku et al. 2003)
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have been associated with the development of RA in
some studies but not in others (Dahlqvist et al. 2002;
Fabris et al. 2002; Huang et al. 2002; Yen et al. 2003;
Barton et al. 2004b; Miterski et al. 2004; Orozco et al.
2004; van der Helm-van Mil et al. 2004; Newman et
al. 2005). Other genes (e.g., IL3 [Yamada et al. 2001],
RUNX1 [Tokuhiro et al. 2003], and HAVCR1 [Chae et
al. 2004]) have demonstrated a positive association in
a single study but have not yet been tested in an inde-
pendent collection for replication. Only PTPN22 has
been convincingly replicated in more than one inde-
pendent study (Begovich et al. 2004; Hinks et al. 2005;
Lee et al. 2005; Orozco et al. 2005; Steer et al. 2005;
Viken et al. 2005; Zhernakova et al. 2005), including
the NARAC samples.
Our replication study was limited to those alleles with
the strongest evidence of a prior association, for efﬁ-
ciency and to minimize multiple-hypothesis testing. We
chose the CT60 variant (rs3087243) of CTLA4, rather
than the serinerthreonine missense SNP at amino acid
17 (rs231775), because the CT60 variant clearly inﬂu-
ences the risk of Graves disease and type 1 diabetes
(Ueda et al. 2003). We chose the slc2F1 (rs2073838)
allele of SLC22A4 because this allele had the strongest
association with RA in a Japanese population (Tokuhiro
et al. 2003). We chose the PADI4_94 allele (rs2240340)
of PADI4 because it had the strongest association in a
Japanese population (Suzuki et al. 2003). IL4 did not
strictly ﬁt the criteria, but it was included in our study
because it is located within the 5q31 cytokine cluster
associated with inﬂammatory bowel disease (Rioux et
al. 2001) and is in very close proximity to SLC22A4
and IL3, both of which have reported evidence of as-
sociation with RA. Although alleles within FCGR3A
satisﬁed the inclusion criteria, they were not studied
further, because FCGR3A was not amenable to geno-
typing by use of our platform. PTPN22 has been tested
in NARAC, but we included it in our analysis to replicate
the result in EIRA and to explore clinically relevant RA
subsets and epistatic interactions.
We also hypothesized that an allele associated with
another autoimmune disease has an increased prior
probability of being associated with RA—compared
with a random allele chosen from the genome—on the
basis of shared pathogenic mechanisms among auto-
immune diseases. We selected seven alleles from ﬁve ad-
ditional genes with convincing evidence of causality in
either inﬂammatory bowel disease (CARD15 [Hugot et
al. 2001; Ogura et al. 2001], DLG5 [Stoll et al. 2004],
and IBD5 [Rioux et al. 2001; Daly and Rioux 2004])
or type 1 diabetes (SUMO4 [Guo et al. 2004] and
CTLA4 [Ueda et al. 2003]), although previous studies
have not shown an association between CARD15 and
RA (Ferreiros-Vidal et al. 2003; Steer et al. 2003; Addo
et al. 2005).
Genotyping
Genotyping was performed, as described elsewhere
(Gabriel et al. 2002), by primer extension of multiplex
products with detection by matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectroscopy (Tang et
al. 1999) with the use of a Sequenom platform. All ge-
notyping was performed at the Broad Institute, except
for the PADI4 variant in NARAC, which was genotyped
at the NIAMS. The average completeness of genotypes
was 97.8% at the Broad Institute and 98.7% at the
NIAMS. Using genotypes performed in replicate (np
), we documented a consensus error rate of 0.5%3,814
in the analyzed data. All SNPs were in Hardy-Weinberg
equilibrium within individual sample collections ( ).P 1 .01
Statistical Analysis
To test our primary hypothesis (that an allele is as-
sociated with the development of RA) and secondary
hypotheses (that particular alleles are associated with a
related RA phenotype reported previously in the liter-
ature) in both EIRA and NARAC samples, one-tailed P
values were calculated using 2-by-2 contingency tables
of allele frequencies and a Fisher’s exact test, and ORs
were reported relative to the published “susceptibility”
allele. Results from the EIRA and NARAC cohorts were
combined by Mantel-Haenszel meta-analysis of the ORs
(Lohmueller et al. 2003), because we hypothesized that
a true susceptibility allele would have an effect in both
populations, despite possible genetic, ethnic, or clinical
differences (Ioannidis et al. 2004). A P value of .05 was
considered signiﬁcant for replication of an allele with
previous evidence of association (Wacholder et al. 2004).
Prior to combining the EIRA and NARAC results, we
tested for homogeneity in the ORs, using a Pearson x2
goodness-of-ﬁt test as described elsewhere (Lohmueller
et al. 2003). The EIRA and NARAC cohorts demon-
strated P values for homogeneity 1.01 for all loci except
PTPN22 ( ). PADI4 ( ) and CTLA4Pp .0002 Pp .03
( ) demonstrated a trend toward signiﬁcant dif-Pp .08
ference. We also tested our primary hypothesis by using
logistic regression, controlling for familial relatedness
in NARAC, age, PTPN22 and SE allele status, and
autoantibody status. Relatedness among siblings was
handled by use of robust (Huber/White/sandwich) var-
iance estimates (Williams 2000). Genotype data from
the NARAC cohort for two genes (PTPN22 [Begovich
et al. 2004; Lee et al. 2005] and CARD15 [Addo et al.
2005]) have been reported elsewhere. The NARAC ge-
notypes are included here for completeness, although
tests of signiﬁcance were based on EIRA genotype data.
Genetic models were tested using a log-linear model of
sample allele frequencies conditional on disease status
(see Genetic Association Models Web site). Power cal-
Table 2
Results Testing Our Primary Hypothesis That an Allele with Prior Evidence of an Association with RA Susceptibility or Another
Autoimmune Disease Replicates in Our Collection of 4,127 Clinical Samples from the EIRA and NARAC Clinical Collections
GENE (VARIANT),
dbSNP,
AND COLLECTION ALLELE
CASES CONTROLS
OR (95% CI) P1/1 1/2 2/2 Frequency 1/1 1/2 2/2 Frequency
PTPN22 (R620W): T
rs2476601:
EIRA 43 389 1,081 .16 16 187 671 .13 1.30 (1.09–1.54) .0015
NARACa 20 236 568 .17 9 125 713 .08 2.18 (1.76–2.70) 132.15# 10
Pooled 1.59 (1.39–1.82) 124.8# 10
PADI4 (PADI4_94): A
rs2240340:
EIRA 244 737 517 .41 153 393 312 .41 1.01 (.89–1.14) .47
NARAC 184 447 264 .46 134 335 279 .40 1.24 (1.08–1.42) .001
Pooled 1.10 (1.00–1.21) .02
TNFRSF1B (R196M): G
rs1061622:
EIRA 84 540 834 .24 61 320 472 .26 .92 (.80–1.05) .90
NARAC 36 272 455 .23 39 243 397 .24 .94 (.79–1.12) .77
Pooled .93 (.83–1.03) .92
RUNX1 (runx1): C
rs2268277:
EIRA 207 705 599 .37 132 391 347 .38 .97 (.86–1.10) .68
NARAC 123 382 324 .38 108 393 342 .36 1.08 (.94–1.24) .16
Pooled 1.02 (.93–1.12) .36
MIF (173 G/C): C
rs755622:
EIRA 51 471 992 .19 35 254 585 .19 1.03 (.88–1.19) .39
NARAC 26 227 579 .17 31 226 590 .17 .98 (.82–1.18) .59
Pooled 1.01 (.90–1.13) .46
HAVCR1 (5383_5397del): Non del
rs6149307:
EIRA 33 389 1,081 .15 19 244 611 .16 .93 (.79–1.09) .83
NARAC 22 232 578 .17 19 202 627 .14 1.21 (1.00–1.46) .03
Pooled 1.04 (.92–1.17) .28
HAVCR1 (5509_5511delCAA): del
EIRA 48 410 1,026 .17 23 269 578 .18 .93 (.80–1.09) .83
NARAC 27 246 491 .20 36 247 396 .24 .80 (.67–.95) .99
Pooled .87 (.77–.98) .99
SLC22A4 (slc2F1): A
rs2073838:
EIRA 13 210 1,293 .08 7 107 760 .07 1.13 (.90–1.42) .15
NARAC 5 131 693 .09 6 128 713 .08 1.03 (.81–1.32) .91
Pooled 1.09 (.92–1.28) .16
IL3 (rIL3-16): C
rs31480:
EIRA 837 567 109 .74 505 298 71 .75 .96 (.84–1.10) .73
NARAC 501 285 40 .78 494 305 48 .76 1.09 (.93–1.29) .15
Pooled 1.01 (.91–1.12) .40
IL4 (590T): T
rs2243250:
EIRA 56 507 940 .21 38 253 584 .19 1.12 (.97–1.30) .07
NARAC 22 219 594 .16 22 254 571 .18 .88 (.73–1.05) .93
Pooled 1.01 (.90–1.14) .40
CTLA4 (CT60): G
rs3087243:
EIRA 595 680 230 .62 337 396 145 .61 1.05 (.93–1.19) .21
NARAC 308 387 133 .61 254 426 165 .55 1.23 (1.08–1.42) .001
Pooled 1.13 (1.03–1.24) .004
(continued)
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Table 2 (continued)
GENE (VARIANT),
dbSNP,
AND COLLECTION ALLELE
CASES CONTROLS
OR (95% CI) P1/1 1/2 2/2 Frequency 1/1 1/2 2/2 Frequency
CARD15 (R702W): T
rs2066844:
EIRA 1 56 1,452 .02 0 36 833 .02 .93 (.61–1.41) .68
NARACa 0 71 752 .05 0 66 773 .05 1.10 (.78–1.55) .32
Pooled 1.03 (.79–1.34) .42
CARD15 (G908R): C
rs2066845:
EIRA 0 11 1,510 .004 0 9 866 .005 .70 (.29–1.69) .85
NARACa 0 28 809 .02 0 31 817 .02 .91 (.55–1.53) .73
Pooled .86 (.55–1.34) .75
CARD15 (1007fs or 3020insC): insC
rs2066847:
EIRA 0 31 1,481 .01 0 24 844 .01 .74 (.43–1.26) .89
NARACa 2 30 805 .02 0 36 812 .02 .96 (.60–1.54) .85
Pooled .86 (.60–1.22) .81
DLG5 (R30Q): A
rs1248696:
EIRA 12 242 1,239 .09 5 148 720 .09 .98 (.80–1.21) .59
NARAC 7 167 653 .11 8 141 688 .09 1.19 (.95–1.49) .08
Pooled 1.07 (.92–1.25) .19
SUMO4 (M55V): G
rs237025:
EIRA 333 729 451 .46 180 458 235 .47 .97 (.86–1.09) .70
NARAC 178 449 202 .49 263 397 189 .54 .79 (.69–.91) .99
Pooled .89 (.81–.97) .99
NOTE.—The putative susceptibility allele is listed. Genotype counts in the two cohorts are expressed relative to the putative
susceptibility allele, where allele “1” is the putative susceptibility allele, and allele “2” is the nonsusceptible allele. One-tailed P
values were calculated on the basis of allele frequency, relative to the putative susceptibility allele. PTPN22 independently replicates
in the EIRA cohort ( ), and PADI4 and CTLA4 replicate in the EIRA and NARAC cohorts combined ( ).Pp .0015 P ! .05
Homogeneity between EIRA and NARAC was calculated using a Pearson x2 goodness-of-ﬁt test, and only PTPN22 demonstrated
a P value !.01 between the two collections. All alleles demonstrated Hardy-Weinberg P values 1.01.
a NARAC data that have been published previously.
culations were performed under a multiplicative model
(ap 0.01) by use of the program by Purcell et al. (2003).
Exploratory and stratiﬁed analyses for PTPN22,
CTLA4, and PADI4 were tested using a Fisher’s exact
test and logistic regression. Stratiﬁed analyses for the
association of PTPN22, CTLA4, and PADI4 with RA
case/control status were performed for three sets of
subgroups: male versus female, RF versus RF, and
CCP versus CCP. Subsequently, RA phenotype anal-
yses for the association of PTPN22, CTLA4, and PADI4
within each nonoverlapping subgroup included com-
parison of male RA cases with female RA cases, com-
parison of RF cases with RF cases, and comparison
of CCP cases with CCP cases. In addition, RF and
CCP cases were compared with all controls. Analysis
of sex-speciﬁc effects for PTPN22 was performed by
pooling the allele frequencies across all three clinical col-
lections and comparing male RF cases with female
RF cases (by logistic regression). Linear regressionwas
used to test whether a genotype inﬂuenced age at disease
onset. Epistatic interactions between pairs of alleles were
tested among PTPN22, CTLA4, PADI4, and HLA-
DRB1 SE alleles, as recently advocated (Marchini et al.
2005), by use of logistic regression to determine whether
genotype distributions were statistically different be-
tween cases and controls. High-resolution genotyping
was available for NARAC, and the SE alleles included
HLA-DRB1*0101, *0401, *0404, *0405, *0408, and
*1001. In the EIRA cohort, HLA-DRB1*01, *04, and
*10 were considered SE alleles (Fries et al. 2002), since
only low-resolution genotyping was available. On the
basis of NARAC data, we estimated that the fraction of
HLA-DRB1*01, *04, and *10 individuals in the EIRA
cohort who carry the SE allele is ∼92%, 96%, and 81%,
respectively. To estimate the false-positive rate, we im-
plemented a Bonferroni correction of our PTPN22 re-
sults for three hypotheses (age, sex, and epistasis with
HLA) and of our CTLA4 and PADI4 results for ﬁve
hypotheses (age, sex, autoantibody status, and epistasis
with HLA or PTPN22).
We performed a meta-analysis of all studies with pub-
lished allele-frequency data for individuals of European
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ancestry, together with our genotype data, as described
elsewhere (Lohmueller et al. 2003). We ﬁrst tested for
homogeneity in the ORs across studies, using a Pearson
x2 goodness-of-ﬁt test. When studies across all ethnic
populations were analyzed together, we observed het-
erogeneity for IL4, TNFRSF1B, and MIF. To minimize
heterogeneity, we excluded studies performed in non-
European populations. Among studies of individuals of
European ancestry, we observed no evidence of signiﬁ-
cant heterogeneity ( ). We calculated the pooledP 1 .01
OR under a ﬁxed-effects model (Mantel-Haenszel meta-
analysis). The original hypothesis-generatingpublication
was excluded from the meta-analysis, when applicable,
to avoid bias from the null hypothesis of no effect
(Hirschhorn et al. 2002). Genotype data were available
for IL4 (Cantagrel et al. 1999), MIF (Miterski et al.
2004), TNFRSF1B (Barton et al. 2001; Dahlqvist et al.
2002; Fabris et al. 2002; Kyogoku et al. 2003; Yen et
al. 2003; van der Helm-van Mil et al. 2004), CARD15
(Ferreiros-Vidal et al. 2003; Steer et al. 2003; Addo et
al. 2005), and CTLA4 (Barton et al. 2004b; Orozco
et al. 2004) but were unavailable from some studies
(Dieude et al. 2002; Maksymowych et al. 2002; New-
man et al. 2005). We excluded MIF data from Barton
et al. (2003), since 25% of the cases with inﬂammatory
polyarthritis failed to develop RA. Only a single study
(Martinez et al. 2005) has tested the PADI4_94 variant
(rs2240340)—the variant was not tested by Barton et
al. (2004a). Across all studies, there were insufﬁcient
data on clinically relevant subsets of RA (e.g., subsets
based on autoantibody status and sex) available to per-
form a more reﬁned meta-analysis.
Results
Description of EIRA and NARAC Clinical Cohorts
and Estimation of Study Power
To maximize our power to detect a true causal RA
allele, we included 14,000 clinical samples from two
distinct cohorts: the EIRA (Stolt et al. 2003; Padyukov
et al. 2004) and the NARAC (Jawaheer et al. 2001,
2004). The clinical features of the EIRA and NARAC
cohorts are shown in table 1. The combined resource of
14,000 total case-control samples provides good power
to detect even modest genetic effects; we have 180%
power to detect the published OR for 14 of the 17 alleles
selected for replication and 150% power to detect an
OR 1.25 for all alleles (see the “Material and Meth-
ods” section). Thus, failure to replicate in our clinical
collection substantially reduces the probability that an
allele is a true causal allele.
Selection of Candidate Alleles and Testing of Primary
Hypothesis
To maximize further our ability to detect a true pos-
itive result, we selected alleles from the published genetic
association studies of RA and other autoimmune dis-
eases. Our goal for the literature review was to identify
alleles with suggestive evidence of association with RA
( in one study or in two or more studies)P ! .001 P ! .05
or convincing association with a different autoimmune
disease. Our primary hypothesis was that an allele that
satisﬁes these criteria is associated with susceptibility to
RA in our collection. Applying our inclusion criteria (see
the “Material and Methods” section) to the RA and
autoimmune literature, we identiﬁed 17 alleles within 14
genes with a putative association with RA or another
autoimmune disease (table 2). Ten alleles within nine
genes had suggestive statistical evidence in favor of an
association with the development of RA. Only the
R620W variant of PTPN22 had been convincingly rep-
licated in more than one study (Hinks et al. 2005; Lee
et al. 2005; Orozco et al. 2005; Steer et al. 2005; Viken
et al. 2005; Zhernakova et al. 2005). Seven alleles within
ﬁve genes had convincing evidence in favor of an as-
sociation with a chronic autoimmune disease (either in-
ﬂammatory bowel disease or type 1 diabetes), although
previous studies have not shown an association between
one of those ﬁve genes, CARD15, and RA (Ferreiros-
Vidal et al. 2003; Steer et al. 2003; Addo et al. 2005).
To determine whether any of the 17 alleles identiﬁed
through our literature review is associated with RA sus-
ceptibility (primary hypothesis), we genotyped each al-
lele in our combined clinical collection of 14,000 case-
control samples. For each allele, we ﬁrst analyzed the
cohorts individually; second, we performed a formal test
for heterogeneity in the OR across the two cohorts; and
third, we combined the samples in a meta-analysis to
provide the best estimate of the OR (under the assump-
tion of a homogeneous effect across cohorts). Of the
17 alleles tested, 3 replicated association, with a one-
tailed P value !.05 (table 2) in the combined samples:
PTPN22, PADI4, and CTLA4. PTPN22 had not been
tested previously in the EIRA cohort and thus repre-
sents an independent replication. The data for each of
the three genes ﬁt best under a multiplicative genetic
model (compared with general, dominant, and recessive
models). The CTLA4 result remained signiﬁcant after
we controlled for self-reported thyroiditis (with which
CTLA4 demonstrates a genetic association [Ueda et al.
2003]) in the NARAC cohort (OR 1.19; 95% CI 1.03–
1.38; ). We did observe a P value !.05 forPp .02
SUMO4 and HAVCR1, but it was for the opposite allele
than the published susceptibility allele. (Because we re-
port our results in table 2 with respect to the published
putative susceptibility allele, SUMO4 and HAVCR1
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Table 3
Results Testing Our Secondary Hypothesis That PTPN22 Is Associated with Autoantibody-Positive
(AutoAb+) but Not Autoantibody-Negative (AutoAb5) Disease in the EIRA Cohort
EIRA
GROUP
ALLELE
MAF
CASES VS. ALL CONTROLS AutoAb VS. AutoAb CASES
T C OR (95% CI) P OR (95% CI) P
RF cases 321 1,565 .17 1.43 (1.19–1.72) .0001 1.37 (1.10–1.72) .003
RF cases 126 844 .13 1.04 (.82–1.32) .73
CCP cases 319 1,499 .18 1.49 (1.23–1.79) .00002 1.43 (1.16–1.77) .0004
CCP cases 151 1,017 .13 1.04 (.83–1.29) .40
NOTE.—The two categories of autoantibodies are RF and CCP. The PTPN22 allele-frequency distri-
bution was compared among RF cases, RF cases, and all EIRA controls. Only RF patients dem-
onstrated a statistically signiﬁcant difference in allele frequency when compared with all controls
( ). The difference between RF and RF cases is statistically signiﬁcant ( ). We alsoPp .0001 Pp .003
stratiﬁed EIRA patients on the basis of CCP antibody status. We found that the allele-frequency dis-
tribution in CCP cases (but not CCP cases) is statistically different from that in controls (Pp
). The difference between CCP and CCP cases is statistically signiﬁcant ( )..00002 Pp .0004
have ORs that are signiﬁcantly !1.0 but have P values
close to 1.) None of the other alleles demonstrated a
signiﬁcant association in these two cohorts (table 2),
even after we controlled for the effects of HLA-DRB1
and PTPN22 (data not shown).
Selection and Testing of Secondary Hypotheses
RA is a heterogeneous disease, and it is possible that
an allele is associated with only a clinical subset of RA.
Therefore, we used our literature review to deﬁne speciﬁc
secondary hypotheses to test in our RA clinical collec-
tion, to ensure that we did not miss a positive associa-
tion. Each secondary hypothesis was based on data from
a previous publication that suggested a speciﬁc genetic
association. The secondary hypotheses relate either to
an RA subphenotype or to a speciﬁc genetic model. We
deﬁned ﬁve secondary hypotheses (with publishedORs):
(1) PTPN22 is associated with RF but not RF disease
(OR 2.0) (Begovich et al. 2004; Lee et al. 2005); (2)
homozygotes for the PADI4 susceptibility allele aremore
likely to be CCP than are the other genotypes com-
bined (OR 3.25) (Suzuki et al. 2003); (3) individuals
homozygous for the putative susceptibility alleles at both
SLC22A4 and RUNX1 have a marked increase in RA
disease risk under a dominant (but not epistatic) model
(OR 9.03) (Tokuhiro et al. 2003); (4) TNFRSF1B is
associated with familial RA but not sporadic RA (OR
1.69) (Barton et al. 2001; Dieude et al. 2002); and
(5) IL3 is associated with RA in females with early-
onset disease (OR 1.89) (Yamada et al. 2001). No oth-
er secondary hypotheses with published statistical evi-
dence were identiﬁed for the remaining 11 alleles. Given
the high ORs, we have 180% power to detect each
hypothesis, with the exception of the one regarding
SLC22A4 and RUNX1, for which there is limited power
to detect an association. We modiﬁed the hypothesis to
ask whether individuals homozygous at RUNX1 and
either heterozygous or homozygous at SLC22A4 (“sus-
ceptible”) were at an increased risk of developing RA,
compared with all other individuals (“nonsusceptible”).
We have 180% power to detect this hypothesis (esti-
mated OR 1.52, on the basis of genotype data from
Tokuhiro et al. [2003]).
Each of our ﬁve secondary hypotheses was tested in
the EIRA and NARAC clinical collections. As shown in
table 3, we replicated the ﬁnding that PTPN22 is as-
sociated with RF disease but not RF disease, using
the previously untested EIRA cohort ( inPp .0001
EIRA). We extend this observation in autoantibody-
positive disease to include an association with CCP
cases but not CCP cases (table 3) in the EIRA cohort,
which is consistent with previously published clinical
observations that these autoantibodies are strongly cor-
related. Using data combined from EIRA and NARAC,
we observe a trend toward an association with PADI4
and anti-CCP antibody status, as previously suggested,
but this was not statistically signiﬁcant (table 4). We
found no signiﬁcant evidence to support an additive
model between SLC22A4 and RUNX1 (table 5), al-
though we have limited power to detect the model
proposed by Tokuriho et al. (2003), given the allele fre-
quencies observed in our population; we found no sig-
niﬁcant evidence to support an association between IL3
and RA in females with early-onset disease (table 6);
and we found no signiﬁcant evidence for an association
of TNFRSF1B with familial RA, represented by the
NARAC affected sibling pairs (table 2).
Exploring Novel Hypotheses for PTPN22
Having established clear evidence for an association
of RA susceptibility with PTPN22 in our samples, we
sought to explore whether the R620W variant is asso-
ciated with a clinically relevant subset of RA. Each
exploratory hypothesis was deﬁned on the basis of
phenotypes of clinical relevance to RA, as established
through epidemiological studies, animal models, or con-
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Table 4
Results Testing Our Secondary Hypothesis That PADI4
Is Associated with CCP+ but Not CCP5 Disease
in the Combined EIRA and NARAC Collections
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 5
Results Testing Our Secondary Hypothesis That
SLC22A4 and RUNX1 Susceptible Genotypes
Additively Inﬂuence the Risk of RA
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
vincing genetic studies of theHLA-DRB1 SE alleles. The
hypotheses were considered exploratory because no sug-
gestive genetic association for the individual genes had
been reported previously (in contrast to our primary and
secondary hypotheses). Our three exploratory hypoth-
eses include: (1) the allele has a greater effect in one sex
than in the other, (2) the allele inﬂuences age at disease
onset, and (3) the allele is epistatic with HLA-DRB1 SE
alleles.
In an analysis of EIRA and NARAC cases, together
with a separate case-only collection of 1,417 RA cases
(“arthritis cohort 3” [Lee et al. 2005]), we found modest
support that the PTPN22 susceptibility allele has a
greater effect in males than in females ( ) (tablePp .03
7). This effect was most prominent in the EIRA cohort
and the arthritis cohort 3. We also observed an age-at-
onset effect for PTPN22: carriers of the susceptible T
allele develop RA 2 years earlier than do those not car-
rying the allele (T/T or C/T mean  SD, 48.2  14.0;
C/C, 50.1  14.3; ). We found no evidencePp .004
to support an epistatic interaction between PTPN22
and SE alleles (data not shown) in the EIRA cohort,
which is consistent with previously published reports
on NARAC (Begovich et al. 2004). After application of
a conservative Bonferroni correction for three hypoth-
eses, the sex effect is no longer signiﬁcant at a P value
!.05, whereas the age-at-onset effect remains signiﬁcant
( ).Pp .012
Stratiﬁed Analyses to Explain Heterogeneity
for PTPN22, CTLA4, and PADI4
We observed a difference in the magnitude of the ge-
netic effect, as measured by the ORs, between the EIRA
and NARAC cohorts: PTPN22 is stronger and more
signiﬁcant in NARAC than in EIRA, and CTLA4 and
PADI4 are only signiﬁcant in the NARAC cohort. As
part of our initial analysis, we formally tested for het-
erogeneity between the ORs of the two cohorts, and
we observed a clear signiﬁcant difference for PTPN22
( ) and a trend toward signiﬁcance for PADI4Pp .0002
( ) and CTLA4 ( ). Because the ascer-Pp .03 Pp .08
tainment criteria and clinical characteristics between the
two cohorts are distinct, we sought to explore whether
a clinically relevant RA subset or an epistatic interaction
might explain the difference in observedORs. Therefore,
we stratiﬁed our analysis by available clinically relevant
subsets of RA (sex, autoantibody status, and age at on-
set) and epistasis with HLA and/or PTPN22.
Stratiﬁed analyses demonstrated that CTLA4 has a
stronger association in patients positive for RF or CCP
autoantibodies (table 8). This effect is most apparent in
a pooled analysis of EIRA and NARAC, when CCP
cases are compared with all controls (OR 1.18; 95% CI
1.07–1.31; ). The result remains signiﬁcantPp .0006
after a Bonferroni correction for ﬁve hypotheses (Pp
). No other clinically relevant subset demonstrated.003
a signiﬁcant association, and we found no evidence of
epistasis between any two combinations of CTLA4 with
HLA or PTPN22 alleles and PADI4 with HLA or
PTPN22 alleles (data not shown). Overall, however, we
were unable to ﬁnd any variable(s) to explain the OR
differences for the three genes between the EIRA and
NARAC cohorts.
Meta-Analysis with Published Data
Alleles with modest impact on disease susceptibility
may be missed by any single study. We therefore per-
formed a meta-analysis, combining our results with pre-
viously published results for individuals of European de-
scent, to determine whether subtle effects across all
published studies could be detected, under the hypoth-
esis that a true susceptibility allele has an effect in dif-
ferent populations despite possible ethnic or clinical
differences. The results, shown in table 9, fail to dem-
onstrate an association of RA with CARD15, IL4, MIF,
or TNFRSF1B. In contrast, the meta-analysis of previ-
ously published data with our data for CTLA4 (table
10) and PADI4 (combined OR 1.12; 95% CI 1.03–1.23
[Martinez et al. 2005]) demonstrates continued evidence
of association with RA.
Discussion
Genetic association is a powerful statisticalmethodology
to identify variants that inﬂuence the risk of developing
a common disease such as RA. However, inconsistent
results across multiple studies make it difﬁcult to inter-
pret which results represent true-positive association
and, therefore, which genes truly inﬂuence the risk of
RA. One explanation for the inconsistent results is in-
sufﬁcient power to detect modest effects in the context
of a low prior probability of a true effect (Hirschhorn
and Daly 2005; Wang et al. 2005). To overcome this
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Table 6
Results Testing Our Secondary Hypothesis That IL3
Is Associated with Early-Onset RA in Females
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 7
Results Testing Our Exploratory Hypothesis That PTNP22 Has a Greater Effect on RA Susceptibility in Males Than in Females
COLLECTION
MALES
( )np 1,073
FEMALES
( )np 3,025
Allele T Allele C MAF OR (95% CI) P Allele T Allele C MAF OR (95% CI) P
EIRA: 1.90 (1.25–2.88) .003 1.20 (.92–1.56) .176
RF cases 111 439 .20 210 1,126 .16
RF cases 32 240 .12 94 604 .13
NARAC: 1.17 (.59–2.31) .65 1.06 (.80–1.41) .694
RF cases 75 425 .15 238 1,216 .16
RF cases 11 73 .13 73 395 .16
Arthritis cohort 3: 1.96 (1.18–3.25 .01 1.34 (1.01–1.79) .05
RF cases 83 433 .16 197 1,231 .14
RF cases 20 204 .09 71 595 .11
Pooled 1.76 (1.31–2.36) .00009 1.19 (1.02–1.40) .015
NOTE.—We performed a case-only analysis stratiﬁed on the basis of sex and RF status. Pooled analysis of the OR of all three collections
demonstrated that the effect of the PTPN22 susceptible T allele is greater in males (OR 1.76) than in females (OR 1.19), a difference that
is statistically signiﬁcant by logistic regression ( ).Pp .03
limitation, we designed a study to test alleles with an
increased prior probability of disease association in a
sample collection powered to detect modest genetic ef-
fects. Our results conﬁrm the association of PTPN22
with autoantibody-positive RA and provide support for
an association with CTLA4 and PADI4. Stratiﬁed anal-
ysis of our data reveals a novel association with age at
onset (PTPN22), sex (PTPN22), and autoantibody-
positive RA (CTLA4), results that need to be replicated
in an independent data set.
Our results in the EIRA cohort, together with other
replication studies (Hinks et al. 2005; Lee et al. 2005;
Orozco et al. 2005; Steer et al. 2005; Viken et al. 2005;
Zhernakova et al. 2005), conﬁrm the hypothesis orig-
inally described by Begovich et al. (2004) in theNARAC
cohort that the PTPN22 R620W variant inﬂuences the
risk of autoantibody-positive RA.We extend the ﬁnding
that PTPN22 is associated with RF disease to include
CCP disease. This result is not surprising, given the
strong correlation between RF and CCP status. How-
ever, it is interesting to note that a more signiﬁcant result
was obtained with CCP status (table 3), which is con-
sistent with the clinical observation that CCP is a more
speciﬁc marker for RA than is RF (Schellekens et al.
2000). Together, these results provide the most con-
vincing evidence to date of a non-MHC gene that in-
ﬂuences the risk of developing RA.
Our stratiﬁed analyses of PTPN22 revealed novel as-
sociations with clinically relevant subsets of RA. We
identiﬁed an association of PTPN22 with age at onset
( ), such that carriers of the susceptible allelePp .004
develop RA ∼2 years earlier than noncarriers do. We
observed a similar result for the HLA-DRB1 SE alleles
and age at onset ( ; data not shown). We alsoPp .0002
observed that PTPN22 has a greater effect in RFmales
than in RF females ( ), a result which is noPp .03
longer signiﬁcant at the level when we correctP ! .05
for our three exploratory hypotheses. Recently, Orozco
et al. (2005) reported a similar trend in male versus
female patients with RA. Limited clinical data for RA
suggest that sex differences indeed exist (Weyand et al.
1998; Kuiper et al. 2001; Tengstrand et al. 2004), ﬁnd-
ings corroborated by animal models of arthritis (Rem-
mers et al. 2002; Adarichev et al. 2003; Meng et al.
2004). These novel ﬁndings require replication in in-
dependent sample collections.
Interpreting the signiﬁcance of CTLA4 and PADI4 is
more challenging, but our data support the hypothesis
that genetic variation within these genes inﬂuences the
risk of developing RA. Our results are signiﬁcant only
in the NARAC cohort, although a trend toward an as-
sociation with CTLA4 is noted in the EIRA cohort.
Because the cohorts are clinically different, we stratiﬁed
our analysis by sex, autoantibody status, and age at
onset. In support of a true-positive association for the
CT60 allele of CTLA4, our results are strengthened in
the EIRA cohort when only CCP cases are compared
with all controls (combined OR 1.18; ) orPp .0006
with CCP cases (OR 1.18; ). This result, ifPp .007
replicated, may indicate that CTLA4 inﬂuences the de-
velopment of RA only in CCP patients. Our results
remain signiﬁcant after a formal meta-analysis with the
published RA literature that includes individuals of Eu-
ropean ancestry. Recently, Lei et al. (2005) demon-
strated an association between the CT60 allele and RA
susceptibility in Han Chinese (OR 1.41; 95% CI 1.10–
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Table 8
Results Testing Our Exploratory Hypothesis That CTLA4 Is Associated with CCP+ but Not CCP5
Disease in Both the EIRA and NARAC Cohorts
COLLECTION
ALLELE
FREQUENCY
CASES VS. ALL CONTROLS CCP VS. CCP CASES
G A OR (95% CI) P OR (95% CI) P
EIRA: 1.18 (1.02–1.38) .03
CCP cases 1,152 656 .64 1.13 (.98–1.29) .08
CCP cases 694 468 .60 .95 (.82–1.11) .51
NARAC: 1.15 (.90–1.48) .26
CCP cases 697 447 .61 1.26 (1.08–1.47) .003
CCP cases 185 137 .57 1.09 (.86–1.39) .48
Pooled: 1.18 (1.03–1.34) .007
CCP cases … … … 1.18 (1.07–1.31) .0006
CCP cases … … … .99 (.87–1.12) .57
NOTE.—The allele-frequency distribution was compared among in CCP cases, CCP cases, and all
controls. Only CCP patients demonstrated a statistically signiﬁcant difference in allele frequency when
compared with all controls (pooled ). The difference between CCP and CCP cases isPp .0006
statistically signiﬁcant ( ).Pp .007
Table 9
Meta-Analysis of IL4, MIF, TNFRSF1B, and CARD15
Allele-Frequency Data
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
1.82; ), providing additional support for aPp .005
true-positive association.
An alternate explanation for the modest association
of CTLA4 and PADI4 with RA in our collection is
that our result is a false-positive. Possible explanations
for a false-positive result include technical artifact, pop-
ulation stratiﬁcation, or an inappropriate statistical
threshold of signiﬁcance. Our genotyping efﬁciency and
accuracy argue strongly against technical artifact (see
the “Material and Methods” section). Both cohorts
were matched on the basis of ethnicity, which reduces
the likelihood of stratiﬁcation. However, it is becoming
increasingly clear that subtle stratiﬁcation exists even in
well-matched cohorts (Freedman et al. 2004; Marchini
et al. 2004). Extensive genotyping of genomic controls
(Pritchard and Donnelly 2001), which is beyond the
scope of this project, is necessary to assess the extent
of stratiﬁcation in each cohort. Ultimately, additional
studies in sufﬁciently powered cohorts of patients with
RA, together with an updated meta-analysis of the pub-
lished literature, are required to determine deﬁnitively
whether genetic variation within PADI4 and/or CTLA4
inﬂuences the risk of developing RA.
If our CTLA4 and PADI4 results in 14,000 samples
are true positives, and the actual allelic OR is ∼1.10 (as
indicated by the pooled analysis), then it is not sur-
prising that smaller studies have failed to detect a
statistically signiﬁcant result. An allele at ∼40% pop-
ulation frequency with an OR of ∼1.10 under a mul-
tiplicative model requires ∼2,700 cases and ∼2,700 con-
trols to have 80% power to detect a true-positive result
(type I error rate 0.05) (see Genetic Power Calculator
Web site), and previous studies were conducted with
fewer samples than this (Barton et al. 2004a, 2004b;
Orozco et al. 2004; Martinez et al. 2005). Consistent
with this explanation, previous studies have shown that
the putative susceptibility alleles were marginally in-
creased in patients with RA, but not to a level that
reached statistical signiﬁcance (see table 10 for CTLA4
meta-analysis).
Our ﬁnding that the majority of previous association
studies in RA may represent false-positive results is con-
sistent with the published literature of other complex
genetic diseases (Ioannidis et al. 2001; Lohmueller et al.
2003). Although it is possible that some of our results
are false negatives, we have 180% power to detect the
published OR in 14 of the 17 alleles selected for rep-
lication (and 150% for all alleles). We selected a nom-
inal P value of .05 as signiﬁcant, to minimize false-
positive results and to maximize our conﬁdence in a
true-positive association. On the basis of empiric and
theoretical data in complex traits, others have advo-
cated similar replication P values (Lohmueller et al.
2003; Wacholder et al. 2004). Furthermore, a formal
meta-analysis failed to detect a subtle effect that may
have been missed by our replication in the NARAC and
EIRA cohorts (table 9). Although we observed no sig-
niﬁcant evidence of genetic heterogeneity across studies,
we excluded individuals of non-European descent. Of
note, there are no formal tests of heterogeneity in patient
selection criteria, and it may be that an alternate analytic
method is necessary to combine effects across studies.
Other explanations for the lack of replication in our
collection include genetic, ethnic, and clinical hetero-
geneity across study populations and the possibility that
we did not test the actual causal allele in a given gene.
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Table 10
Meta-Analysis of CTLA4 CT60 Allele (rs3087243)
COLLECTION
ALLELE
FREQUENCY OR (95% CI) PG A
EIRA: 1.05 (.93–1.19) .21
Cases 1,870 1,140 .62
Controls 1,070 686 .61
NARAC: 1.23 (1.08–1.42) .001
Cases 1,003 653 .61
Controls 934 756 .55
Barton et al. (2004b): 1.04 (.90–1.20) .64
Cases 820 618 .57
Controls 848 662 .56
Orozco et al. (2004): .98 (.81–1.19) .84
Cases 432 434 .50
Controls 401 395 .50
Pooled 1.08 (1.01–1.17) .01
NOTE.—Allele-frequency data of RA cases versus controls were compared across
four study populations, by use of a ﬁxed-effects (Mantel-Haenszel) meta-analysis of
the ORs. No signiﬁcant heterogeneity was observed among the four studies. No data
on CCP status were available from the two published studies to compare CCP
cases only (for which we observed a more signiﬁcant result).
It is possible that a true susceptibility allele in one ethnic
population has no effect in a different ethnic population
(“ethnic heterogeneity”). There is little evidence to sup-
port this hypothesis (Ioannidis et al. 2004), although a
thorough evaluation is not yet possible, given the limited
number of true susceptibility alleles tested across mul-
tiple ethnic populations. Differences in clinical features
or ascertainment criteria across RA collections may ac-
count for the inability to replicate. For example, we
observe a more signiﬁcant association between RA and
CTLA4 and PTPN22 alleles when CCP status is taken
into consideration. In an attempt to control for clinical
differences, we used our literature review to deﬁne sec-
ondary hypotheses that test for relevant subsets, but we
found no evidence of association. Finally, we cannot
exclude that other variants within these genes may be
associated with RA. We selected alleles with the most-
signiﬁcant association from a previous study. If we as-
sume that an allele is either the putative causal allele or
in very strong LD with the causal allele, then our study
design should replicate the original ﬁnding. Compre-
hensive testing of genetic variation within each gene
may reveal alternate alleles that contribute to RA sus-
ceptibility, as recently suggested by a study of PTPN22
(Carlton et al. 2005).
We observed a difference in the ORs between the
EIRA and NARAC cohorts for PTPN22, CTLA4, and
PADI4. There are two possible explanations for the
differences. First, the effect in NARAC and EIRA could
actually be the same, with the different ORs simply
reﬂecting sampling variance across the two populations.
This is clearly not the case for PTPN22, which dem-
onstrates a statistically signiﬁcant difference between
the two cohorts. Second, the OR in NARAC and EIRA
could indeed be different as a result of ascertainment,
clinical severity, “genetic loading” of affected sibling
pairs, or an unmeasured variable. Our stratiﬁed analyses
failed to identify any clear explanation for the differ-
ence, although we were unable to correct for disease
severity, because of the lack of a suitable clinical variable
in EIRA (e.g., disease activity score or radiographic ero-
sions). The statistically signiﬁcant differences in theORs
observed for CTLA4 and PADI4 are sufﬁciently modest
such that we do not believe it is possible to determine
these two association models at present. Future studies
aimed at identiﬁcation of covariates will be important
for understanding the impact of these genes on RA clin-
ical heterogeneity.
We did observe a P value !.05 for HACVR1 and
SUMO4, but not with the published susceptibility allele.
Therefore, these results may represent statistical ﬂuc-
tuation rather than a true-positive association. Re-
cent data have called into question the validity of the
SUMO4 association with type 1 diabetes (Park et al.
2005; Qu et al. 2005; Smyth et al. 2005). It should also
be noted that the allele frequency of the SLC22A4 var-
iant tested is signiﬁcantly lower in our collection (minor-
allele frequency ) than in the Japanese[MAF] ≈ 0.08
population ( ), which limits our power toMAF ≈ 0.31
detect a true association (especially under a recessive
genetic model). Studies in additional populations are
necessary to test whether these or alternate alleles are
associated with RA.
In conclusion, our results replicate the ﬁnding that
PTPN22 is associated with RF RA and suggest the
novel hypotheses that the allele inﬂuences age at RA
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onset and has a greater effect in males than in females.
In addition, our study provides support for association
of RA with CTLA4 and PADI4, a result that will need
to be conﬁrmed in additional studies. We ﬁnd no evi-
dence to support an association for the remaining al-
leles, which suggests that these alleles are not associated
with RA with an OR 1.10. These results add to our
understanding of the genetic basis of RA and empha-
size the need for large collections of patients, updated
meta-analysis, and stringent interpretation of statistical
signiﬁcance in future RA candidate-gene association
studies.
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